136 related articles for article (PubMed ID: 20407331)
1. True cytokeratin 8/18 immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Hsu JD; Yao CC; Lee MY; Kok LF; Wang PH; Tyan YS; Han CP
Int J Gynecol Pathol; 2010 May; 29(3):282-9. PubMed ID: 20407331
[TBL] [Abstract][Full Text] [Related]
2. Five commonly used markers (p53, TTF1, CK7, CK20, and CK34betaE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
Han CP; Kok LF; Lee MY; Wu TS; Ruan A; Cheng YW; Wang PH; Koo CL; Tyan YS
Arch Gynecol Obstet; 2010 Feb; 281(2):317-23. PubMed ID: 19444461
[TBL] [Abstract][Full Text] [Related]
3. A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Han CP; Lee MY; Kok LF; Wu TS; Cheng YW; Wang PH; Yue CH; Tyan YS
Arch Gynecol Obstet; 2010 May; 281(5):845-50. PubMed ID: 19847454
[TBL] [Abstract][Full Text] [Related]
4. Comparing the scoring mechanisms of p16INK4a immunohistochemistry based on independent nucleic stains and independent cytoplasmic stains in distinguishing between endocervical and endometrial adenocarcinomas in a tissue microarray study.
Kok LF; Lee MY; Tyan YS; Wu TS; Cheng YW; Kung MF; Wang PH; Han CP
Arch Gynecol Obstet; 2010 Feb; 281(2):293-300. PubMed ID: 19418062
[TBL] [Abstract][Full Text] [Related]
5. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
[TBL] [Abstract][Full Text] [Related]
6. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Han CP; Lee MY; Kok LF; Ruan A; Wu TS; Cheng YW; Tyan YS; Lin CY
Int J Gynecol Pathol; 2009 Sep; 28(5):489-96. PubMed ID: 19696622
[TBL] [Abstract][Full Text] [Related]
7. Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Yao CC; Kok LF; Lee MY; Wang PH; Wu TS; Tyan YS; Cheng YW; Kung MF; Han CP
Arch Gynecol Obstet; 2009 Sep; 280(3):405-13. PubMed ID: 19153755
[TBL] [Abstract][Full Text] [Related]
8. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma.
McCluggage WG; Jenkins D
Int J Gynecol Pathol; 2003 Jul; 22(3):231-5. PubMed ID: 12819388
[TBL] [Abstract][Full Text] [Related]
9. Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough?
Liao CL; Hsu JD; Lee MY; Kok LF; Li YJ; Wang PH; Yao CC; Han CP
Virchows Arch; 2010 Apr; 456(4):377-86. PubMed ID: 20221633
[TBL] [Abstract][Full Text] [Related]
10. Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
Onuma K; Dabbs DJ; Bhargava R
Int J Gynecol Pathol; 2008 Jul; 27(3):418-25. PubMed ID: 18580321
[TBL] [Abstract][Full Text] [Related]
11. Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study.
Han CP; Kok LF; Wang PH; Wu TS; Tyan YS; Cheng YW; Lee MY; Yang SF
Mod Pathol; 2009 Jun; 22(6):797-806. PubMed ID: 19347018
[TBL] [Abstract][Full Text] [Related]
12. p16 INK4 and CEA can be mutually exchanged with confidence between both relevant three-marker panels (ER/Vim/CEA and ER/Vim/p16 INK4) in distinguishing primary endometrial adenocarcinomas from endocervical adenocarcinomas in a tissue microarray study.
Han CP; Lee MY; Tyan YS; Kok LF; Yao CC; Wang PH; Hsu JD; Tseng SW
Virchows Arch; 2009 Oct; 455(4):353-61. PubMed ID: 19763614
[TBL] [Abstract][Full Text] [Related]
13. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas.
McCluggage WG; Sumathi VP; McBride HA; Patterson A
Int J Gynecol Pathol; 2002 Jan; 21(1):11-5. PubMed ID: 11781517
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.
Jones MW; Onisko A; Dabbs DJ; Elishaev E; Chiosea S; Bhargava R
Int J Gynecol Cancer; 2013 Feb; 23(2):380-4. PubMed ID: 23318908
[TBL] [Abstract][Full Text] [Related]
15. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
16. Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
Liao CL; Lee MY; Tyan YS; Kok LF; Wu TS; Koo CL; Wang PH; Chao KC; Han CP
J Transl Med; 2009 May; 7():37. PubMed ID: 19476621
[TBL] [Abstract][Full Text] [Related]
17. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
18. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study.
Castrillon DH; Lee KR; Nucci MR
Int J Gynecol Pathol; 2002 Jan; 21(1):4-10. PubMed ID: 11781516
[TBL] [Abstract][Full Text] [Related]
19. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin.
Saad RS; Mashhour M; Noftech-Mozes S; Ismiil N; Dubé V; Ghorab Z; Faragalla H; Khalifa MA
Int J Gynecol Pathol; 2012 Jan; 31(1):57-65. PubMed ID: 22123724
[TBL] [Abstract][Full Text] [Related]
20. [Expression of glucose transporter-1 in endometrial hyperplasia and well-differentiated endometrioid adenocarcinoma].
Liu AJ; Hou N; Chen LZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):398-400. PubMed ID: 12940086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
